PASSAGE BIO, INC. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
PASSAGE BIO, INC. (PASG) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $39.17 million as of 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2025-03-04
- 2024-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $39.17M.
- 2024-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $52.50M.
- 2024-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $67.07M.
- 2024-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $67.82M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2024-12-31 | $39.17M 10-K · filed 2025-03-04 |
| 2024-09-30 | $52.50M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $67.07M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $67.82M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $92.63M 10-K · filed 2024-03-04 |
| 2023-09-30 | $99.39M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $121.53M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $134.83M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $155.97M 10-K · filed 2023-03-06 |
| 2021-12-31 | $187.22M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |